These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16456863)

  • 1. An open trial of paroxetine for the "offensive subtype" of taijin kyofusho and social anxiety disorder.
    Nagata T; van Vliet I; Yamada H; Kataoka K; Iketani T; Kiriike N
    Depress Anxiety; 2006; 23(3):168-74. PubMed ID: 16456863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of milnacipran on insight and stress coping strategy in patients with Taijin Kyofusho.
    Nagata T; Wada A; Yamada H; Iketani T; Kiriike O
    Int J Psychiatry Clin Pract; 2005; 9(3):193-8. PubMed ID: 24937790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Features of the offensive subtype of Taijin-Kyofu-Sho in US and Korean patients with DSM-IV social anxiety disorder.
    Choy Y; Schneier FR; Heimberg RG; Oh KS; Liebowitz MR
    Depress Anxiety; 2008; 25(3):230-40. PubMed ID: 17340609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taijin Kyofusho in university students: patterns of fear and predispositions to the offensive variant.
    Tarumi S; Ichimiya A; Yamada S; Umesue M; Kuroki T
    Transcult Psychiatry; 2004 Dec; 41(4):533-46. PubMed ID: 15709650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The offensive subtype of Taijin-kyofu-sho in New York City: the phenomenology and treatment of a social anxiety disorder.
    Clarvit SR; Schneier FR; Liebowitz MR
    J Clin Psychiatry; 1996 Nov; 57(11):523-7. PubMed ID: 8968301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taijin kyofusho: a form of social anxiety disorder that responds to serotonin reuptake inhibitors?
    Matsunaga H; Kiriike N; Matsui T; Iwasaki Y; Stein DJ
    Int J Neuropsychopharmacol; 2001 Sep; 4(3):231-7. PubMed ID: 11602029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.
    Liebowitz MR; Gelenberg AJ; Munjack D
    Arch Gen Psychiatry; 2005 Feb; 62(2):190-8. PubMed ID: 15699296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled-release paroxetine in the treatment of patients with social anxiety disorder.
    Lepola U; Bergtholdt B; St Lambert J; Davy KL; Ruggiero L
    J Clin Psychiatry; 2004 Feb; 65(2):222-9. PubMed ID: 15003077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience with paroxetine in social anxiety disorder.
    Baldwin DS
    Int Clin Psychopharmacol; 2000 Jul; 15 Suppl 1():S19-24. PubMed ID: 10994679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic advances: paroxetine for the treatment of social anxiety disorder.
    Lydiard RB; Bobes J
    Depress Anxiety; 2000; 11(3):99-104. PubMed ID: 10875050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind placebo-controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa.
    Stein DJ; Berk M; Els C; Emsley RA; Gittelson L; Wilson D; Oakes R; Hunter B
    S Afr Med J; 1999 Apr; 89(4):402-6. PubMed ID: 10341825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder.
    Book SW; Thomas SE; Randall PK; Randall CL
    J Anxiety Disord; 2008; 22(2):310-8. PubMed ID: 17448631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptoms of offensive type Taijin-Kyofusho among Australian social phobics.
    Kim J; Rapee RM; Gaston JE
    Depress Anxiety; 2008; 25(7):601-8. PubMed ID: 17607747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paroxetine in social phobia.
    Mancini C; Ameringen MV
    J Clin Psychiatry; 1996 Nov; 57(11):519-22. PubMed ID: 8968300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
    Pelissolo A
    Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder.
    Wagner KD; Berard R; Stein MB; Wetherhold E; Carpenter DJ; Perera P; Gee M; Davy K; Machin A
    Arch Gen Psychiatry; 2004 Nov; 61(11):1153-62. PubMed ID: 15520363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Japanese form of social anxiety (taijin kyofusho): frequency and correlates in two generations of the same family.
    Essau CA; Sasagawa S; Ishikawa S; Okajima I; O'Callaghan J; Bray D
    Int J Soc Psychiatry; 2012 Nov; 58(6):635-42. PubMed ID: 21911434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial.
    Stein MB; Liebowitz MR; Lydiard RB; Pitts CD; Bushnell W; Gergel I
    JAMA; 1998 Aug; 280(8):708-13. PubMed ID: 9728642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder.
    Liebowitz MR; Stein MB; Tancer M; Carpenter D; Oakes R; Pitts CD
    J Clin Psychiatry; 2002 Jan; 63(1):66-74. PubMed ID: 11838629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.